WuXi Biologics (Cayman) Inc. (WUXIBIO) income statement

HKSE · Healthcare · Biotechnology · 14,705 employees · CEO Zhisheng Chen

Price: HK$44.60 +0.27%
Market cap: HK$184B
Enterprise value: CN¥149B
Last report: Q2 '26 filed 2026-06-30
Next report: 2027-03-23

WuXi Biologics (Cayman) Inc. (WUXIBIO) reported revenue of CN¥11.8B for Q2 '26 (+18.4% year on year), operating income of CN¥3.73B (31.6% of revenue) and net income of CN¥2.44B. Over the last two half-years revenue was CN¥23.6B.

Income statement

Income statement	Q4 '20	Q2 '21	Q4 '21	Q2 '22	Q4 '22	Q2 '23	Q4 '23	Q2 '24	Q4 '24	Q2 '25	Q4 '25	Q2 '26
Revenue	CN¥3.67B	CN¥4.41B	CN¥5.88B	CN¥7.21B	CN¥8.06B	CN¥8.49B	CN¥8.54B	CN¥8.57B	CN¥10.1B	CN¥9.95B	CN¥11.8B	CN¥11.8B
Cost of revenue	CN¥1.92B	CN¥2.11B	CN¥3.35B	CN¥3.79B	CN¥4.75B	CN¥4.93B	CN¥5.27B	CN¥5.22B	CN¥5.8B	CN¥5.7B	CN¥6.07B	CN¥6.34B
Gross profit	CN¥1.75B	CN¥2.3B	CN¥2.53B	CN¥3.41B	CN¥3.31B	CN¥3.56B	CN¥3.27B	CN¥3.35B	CN¥4.3B	CN¥4.25B	CN¥5.77B	CN¥5.45B
Research & development	CN¥185M	CN¥115M	CN¥392M	CN¥271M	CN¥418M	CN¥341M	CN¥451M	CN¥344M	CN¥422M	CN¥344M	CN¥517M	CN¥424M
Sales & marketing	CN¥46M	CN¥60.4M	CN¥64.3M	CN¥67.1M	CN¥95.8M	CN¥105M	CN¥189M	CN¥223M	CN¥251M	CN¥270M	CN¥339M	CN¥323M
General & administrative	CN¥308M	CN¥348M	CN¥528M	CN¥520M	CN¥749M	CN¥680M	CN¥816M	CN¥773M	CN¥901M	CN¥781M	CN¥923M	CN¥860M
Other operating expenses	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	-CN¥388M	CN¥0	CN¥65.2M	CN¥5.94M
Operating expenses	CN¥521M	CN¥244M	CN¥611M	CN¥513M	CN¥905M	CN¥1.03B	CN¥1.62B	CN¥1.53B	CN¥1.15B	CN¥1.53B	CN¥1.85B	CN¥1.72B
Operating income	CN¥1.15B	CN¥1.64B	CN¥1.53B	CN¥2.48B	CN¥1.87B	CN¥2.3B	CN¥1.65B	CN¥1.82B	CN¥3.15B	CN¥2.72B	CN¥3.92B	CN¥3.73B
Interest income	CN¥37M	CN¥6.51M	CN¥16.5M	CN¥34.7M	CN¥21.8M	CN¥3.98M	CN¥64.7M	CN¥208M	CN¥350M	CN¥121M	CN¥216M	CN¥203M
Interest expense	CN¥74.4M	CN¥231M	CN¥11.3M	CN¥558M	CN¥93.9M	CN¥0	CN¥0	CN¥0	CN¥158M	CN¥0	CN¥58.5M	CN¥43.9M
Other non-operating income (gains on investments, FX ...)	-CN¥286K	CN¥7.34M	CN¥10.7M	CN¥6.27M	-CN¥14.5M	CN¥0	CN¥15.6M	CN¥0	-CN¥18.2M	CN¥0	-CN¥6.75M	CN¥0
Total non-operating income	CN¥113M	CN¥411M	CN¥394M	CN¥440M	CN¥576M	CN¥227M	-CN¥1.14M	CN¥189M	-CN¥328M	CN¥604M	CN¥13.3M	-CN¥309M
Income before tax	CN¥1.26B	CN¥2.06B	CN¥1.93B	CN¥2.93B	CN¥2.43B	CN¥2.53B	CN¥1.64B	CN¥2.01B	CN¥2.83B	CN¥3.33B	CN¥3.93B	CN¥3.42B
Income tax	CN¥299M	CN¥175M	CN¥309M	CN¥309M	CN¥499M	CN¥191M	CN¥412M	CN¥228M	CN¥661M	CN¥571M	CN¥952M	CN¥503M
Net income	CN¥953M	CN¥1.84B	CN¥1.55B	CN¥2.54B	CN¥1.89B	CN¥2.27B	CN¥1.13B	CN¥1.5B	CN¥1.86B	CN¥2.34B	CN¥2.57B	CN¥2.44B
EPS (basic)	CN¥0.22	CN¥0.42	CN¥0.36	CN¥0.58	CN¥0.42	CN¥0.52	CN¥0.26	CN¥0.35	CN¥0.46	CN¥0.55	CN¥0.61	CN¥0.60
EPS (diluted)	CN¥0.22	CN¥0.42	CN¥0.34	CN¥0.58	CN¥0.44	CN¥0.52	CN¥0.26	CN¥0.35	CN¥0.43	CN¥0.55	CN¥0.61	CN¥0.58
Shares (basic, weighted)	4.27B	4.39B	4.42B	4.37B	4.37B	4.35B	4.35B	4.26B	4.08B	4.19B	4.17B	4.1B
Shares (diluted, weighted)	4.27B	4.41B	4.44B	4.39B	4.37B	4.35B	4.35B	4.26B	4.23B	4.19B	4.17B	4.18B
Depreciation & amortization	CN¥246M	CN¥336M	CN¥372M	CN¥490M	CN¥301M	CN¥662M	CN¥720M	CN¥784M	CN¥858M	CN¥860M	CN¥888M	CN¥938M
EBITDA	CN¥1.39B	CN¥1.98B	CN¥1.9B	CN¥2.97B	CN¥2.17B	CN¥2.96B	CN¥2.35B	CN¥2.6B	CN¥4.03B	CN¥3.58B	CN¥4.81B	CN¥4.67B

Income statement	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	CN¥989M	CN¥1.62B	CN¥2.53B	CN¥3.98B	CN¥5.61B	CN¥10.3B	CN¥15.3B	CN¥17B	CN¥18.7B	CN¥21.8B
Cost of revenue	CN¥600M	CN¥958M	CN¥1.52B	CN¥2.32B	CN¥3.08B	CN¥5.46B	CN¥8.54B	CN¥10.2B	CN¥11B	CN¥11.8B
Gross profit	CN¥389M	CN¥661M	CN¥1.02B	CN¥1.66B	CN¥2.53B	CN¥4.83B	CN¥6.72B	CN¥6.83B	CN¥7.65B	CN¥10B
Research & development	CN¥53.3M	CN¥74.5M	CN¥169M	CN¥260M	CN¥304M	CN¥502M	CN¥683M	CN¥793M	CN¥766M	CN¥860M
Sales & marketing	CN¥15.3M	CN¥27.6M	CN¥42.4M	CN¥77.1M	CN¥94.4M	CN¥125M	CN¥163M	CN¥294M	CN¥474M	CN¥609M
General & administrative	CN¥93.7M	CN¥134M	CN¥228M	CN¥367M	CN¥511M	CN¥876M	CN¥1.27B	CN¥1.5B	CN¥1.67B	CN¥1.7B
Other operating expenses	-CN¥438K	-CN¥12.2M	-CN¥116M	-CN¥102M	-CN¥138M	CN¥139M	CN¥267M	-CN¥204M	-CN¥237M	CN¥65.2M
Operating expenses	CN¥162M	CN¥224M	CN¥324M	CN¥602M	CN¥771M	CN¥1.64B	CN¥2.38B	CN¥2.38B	CN¥2.68B	CN¥3.38B
Operating income	CN¥202M	CN¥349M	CN¥876M	CN¥1.11B	CN¥1.5B	CN¥3.19B	CN¥4.34B	CN¥4.45B	CN¥4.97B	CN¥6.64B
Interest income	CN¥413K	CN¥8.75M	CN¥78.4M	CN¥63.9M	CN¥80.9M	CN¥58M	CN¥107M	CN¥219M	CN¥350M	CN¥384M
Interest expense	CN¥24.2M	CN¥35.7M	CN¥0	CN¥19.6M	CN¥42.7M	CN¥39.2M	CN¥64.4M	CN¥158M	CN¥158M	CN¥139M
Other non-operating income (gains on investments, FX ...)	CN¥25.9M	CN¥111M	-CN¥43.6M	CN¥0	-CN¥286K	CN¥18M	-CN¥8.24M	CN¥118M	-CN¥18.2M	-CN¥6.75M
Total non-operating income	-CN¥50.1M	-CN¥147M	CN¥43.6M	CN¥69.6M	CN¥464M	CN¥805M	CN¥1.02B	-CN¥276M	-CN¥139M	CN¥617M
Income before tax	CN¥176M	CN¥304M	CN¥738M	CN¥1.13B	CN¥1.97B	CN¥3.99B	CN¥5.36B	CN¥4.17B	CN¥4.83B	CN¥7.26B
Income tax	CN¥34.8M	CN¥51.1M	CN¥107M	CN¥116M	CN¥273M	CN¥485M	CN¥808M	CN¥603M	CN¥889M	CN¥1.52B
Net income	CN¥141M	CN¥253M	CN¥631M	CN¥1.01B	CN¥1.69B	CN¥3.39B	CN¥4.42B	CN¥3.4B	CN¥3.36B	CN¥4.91B
EPS (basic)	CN¥0.04	CN¥0.08	CN¥0.16	CN¥0.27	CN¥0.43	CN¥0.81	CN¥1.06	CN¥0.82	CN¥0.82	CN¥1.16
EPS (diluted)	CN¥0.04	CN¥0.07	CN¥0.16	CN¥0.25	CN¥0.40	CN¥0.77	CN¥1.01	CN¥0.77	CN¥0.78	CN¥1.16
Shares (basic, weighted)	3.4B	3.22B	3.94B	4B	4.21B	4.4B	4.17B	4.16B	4.08B	4.18B
Shares (diluted, weighted)	3.4B	3.48B	3.94B	4B	4.21B	4.42B	4.38B	4.35B	4.23B	4.18B
Depreciation & amortization	CN¥93.2M	CN¥123M	CN¥144M	CN¥221M	CN¥303M	CN¥482M	CN¥801M	CN¥1.17B	CN¥1.44B	CN¥1.72B
EBITDA	CN¥319M	CN¥471M	CN¥881M	CN¥1.37B	CN¥2.31B	CN¥4.51B	CN¥6.22B	CN¥5.5B	CN¥6.43B	CN¥8.37B

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.

Revenue, operating income and growth

quarterly

Margins

quarterly

Costs as % of revenue

quarterly

The other statements

Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.